The potential of protein kinase C as A target for anticancer treatment

Pharmacology and Therapeutics

Volumn 59, Issue 3, 1993, Pages 257-280

  Basu, Alakananda ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME ACTIVATOR; ENZYME INHIBITOR; PROTEIN KINASE C; UNINDEXED DRUG;

CANCER THERAPY; CARCINOGENESIS; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE; HUMAN; NEOPLASMS; PROTEIN KINASE C; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027435064     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(93)90070-T     Document Type: Review

References (191)

1. Affinity-purified c-jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity
2. Elevated activities of protein kinase C and tyrosine kinase correlate to leukemic cell aggressiveness
3. Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C
4. Role of protein kinase C in the modulation of multidrug resistance: expression of the atypical γ isoform of protein kinase C does not confer increased resistance to doxorubicin
5. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models
6. Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a and its mechanism of action
7. Protein kinase C activity and expression in normal and adenomatous human pituitaries
8. The role of protein kinase C and the phosphatidylinositol cycle in multidrug resistance in human ovarian cancer cells
9. Protein kinase C-γ is present in adriamycin resistant HL-60 leukemia cells
10. Lipid peroxidation, phosphoinositide turnover and protein kinase C activation in human platelets treated with anthracyclines and their complexes with
11. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1
12. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II)
13. Cellular sensitization to cis-diamminedichloroplatinum(II) by novel analogs of protein kinase C activator lyngbyatoxin A
14. Structural requirements of lyngbyatoxin A for activation and downregulation of protein kinase C
15. Constitutive presence of a catalytic fragment of protein kinase Cϵ in a small cell lung carcinoma cell line
16. Mechanism of protein kinase C inhibition by sphingosine
17. Bryostatin, a non-phorbal macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor
18. Inositol phosphate, a novel second messenger in cellular signal transduction
19. Modes of inhibition of protein kinase C by triphenylacrylonitrile antiestrogens
20. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells
21. Protein kinase C as the receptor for the phorbol esters tumor promoters: sixth Rhoads memorial award lecture
22. Long-chain (Sphingoid) bases inhibit multistage carcinogenesis in mouse C3H/10T1/2 cells treated with radiation and phorbol 12-myristate 13-acetate
23. Transformation by a ras oncogene causes increased expression of protein kinase C-α and decreased expression of protein kinase C-ϵ
24. Failure of wild-type or a mutant form of protein kinase C-α to transform fibroblasts
25. Expression of four protein kinase C isoforms in rat fibroblasts: distinct subcellular distribution and regulation by calcium and phorbol esters
26. Expression of four protein kinase C isoforms in rat fibroblasts: differential alterations in ras-, src- and fos-transformed cells
27. Inhibition of protein kinase C by sphingosine correlates with the presence of positive charge
28. Activation of protein kinase C decreases phosphorylation of c-jun at sites that negatively regulate its DNA-binding activity
29. Modulation by staurosporine of phorbol-ester-induced effects on growth and protein kinase C localization in A549 human lung-carcinoma cells
30. Inhibition of protein kinase C by calphostin C is light-dependent
31. Modulation of drug permeability in Chinese hamster ovary cells: possible role for phosphorylation of surface glycoproteins
32. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters
33. Evidence that adriamycin resistance in Chinese hamster lung cells is regulated by phosphorylation of a plasma membrane glycoprotein
34. Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells
35. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells
36. Regulation by phorbol ester and protein kinase C inhibitors and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human KB cells
37. Activation of MDRI (P-glycoprotein) gene expression in human cells by protein kinase C agonists
38. Synthesis of diacyglycerol de novo is responsible for permanent activation and down-regulation of protein kinase C in transformed cells
39. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression
40. Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells
41. Evidence for a role of phosphatidylcholine-hydrolysing phospholipase C in the regulation of protein kinase C by ras and src oncogenes
42. Staurosporine induces protein kinase C agonist effects and maturation of normal and neoplastic mouse keratinocytes in vitro
43. Specific binding of phorbol ester tumor promoters
44. Aflatoxin-transformed C3H/10T1/2 cells overexpress protein kinase C and have an altered response to phorbol ester treatments
45. Cell membrane signaling as target in cancer therapy: inhibitory effect of N,N-dimethy and N,N,N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice
46. Stable expression of a cDNA encoding rat brain protein kinase C-βI confers a multidrug-resistant phenotype on rat fibroblasts
47. Transient protection of cultured human cells against antitumor agents by 12-O-tetradecanoylphorbol-13-acetate
48. Phorbol esters induce multidrug resistance in human breast cancer cells
49. Activation in vitro of NF-kB by phosphorylation of its inhibitor lkB
50. Expression of proto-oncogene c-jun during differentiation of B-chronic lymphocytic leukemia
51. Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport
52. 2+- and phospholipid-independent activation of protein kinase C by selective oxidative modification of the regulatory domain
53. Reversible oxidative activation and inactivation of protein kinase C by the mitogen/tumor promoter periodate
54. Potentiation of the activity of 1-β-d-arabinofuranosylcytosine by the proetin kinase C activator bryostatin 1 HL-60 cells: association with enhanced fragmentation of mature DNA
55. Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro
56. 2+-dependent protein kinases in human colon carcinomas
57. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-d-arabinofuranosylcytosine
58. Assessment of protein kinase C isozymes by enzyme immunoassay and overexpression of type II in thyroid adenocarcinoma
59. r 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumore cells: effects of verapamil, trifluoperazine and phorbol esters
60. Tumorigenicity-associated expression of protein kinase C isoforms in rhabdomyosarcoma-derived cells
61. Aminoacridines, potent inhibitors of protein kinase C
62. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and human platelets
63. The adriamycin-iron(III) complex is a potent inhihitor of protein kinase C
64. Alkyllysophospholipid ET-18-OCH3 acts as an activator of protein kinase C in HL-60 cells
65. 2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cells lines HL-60 and K562, and its inhibition by alkyl-lysophospholipid
66. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin
67. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A
68. 3H]-staurosporine on various protein kinases
69. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C
70. Selective translocation of βII-protein kinase C to the nucleus of human promyelocytic (HL-60) leukemia cells
71. Enhancement of the antiproliferative effect of cis-diamminedichloro-platinum(II) and nitrogen mustard by inhibitors of protein kinase C
72. Synergistic enhancement of the antiproliferative activity of cis-diammine-dichloroplatinum(II) by the ether lipid analog BM41440, an inhibitor of protein kinase C
73. Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin
74. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity
75. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain
76. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts
77. Cells that overproduce protein kinase C are more susceptible to transformation by an activated H-ras oncogene
78. 2+-activated and phospholipid-dependent protein kinase
79. Enhancement of inositol phospholipid metabolism and activation of protein kinase C in ras-transformed rat fibroblasts
80. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues II
81. Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate
82. Inhibition of MCF-7 cell growth by 12-O-tetradecanoylphorbol 13-acetate
83. Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells
84. Effects of bryostatins and retinoic acid on phorbol ester- and diacylgylcerol-induced squamous differentiation in human tracheobronchial epithelial cells
85. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases
86. 2+-dependent protein kinases in heart and inhibition of their phosphorylation by palmitoylcarnitine
87. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines
88. Arachidonic and cis-unsaturated fatty acids induce selective platelet substrate phosphorylation through activation of cytosolic protein kinase C
89. Activation of protein kinase C by oleic acid-determination and analysis of inhibition by detergent micelles and physiologic membranes: requirement for free oleate
90. Regulation of c-jun gene expression in HL-60 leukemia cells by 1-β-d-arabinofuranosylcytosine Potential involvement of a protein kinase C-dependent mechanism
91. Selective redistribution of protein kinase C isozymes by thapsigargin and staurosporine
92. Activation of calcium- and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover
93. Limited proteolysis of protein kinase C subspecies by calcium-dependent neutral protease (calpain)
94. Temporal changes in intracellular distribution of protein kinase C during differentiation of human leukemia HL 60 cells induced by phorbol ester
95. Calphostin C (UCN-1028c), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C
96. Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas
97. 2+, phospholipid-dependent protein kinase associated with plasma membrane
98. Bryostatiin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60
99. Varied differentiation responses of human leukemias to bryostatin 1
100. Protein kinase C activation by anthracyclines in Swiss 3T3 cells
101. elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells
102. In vitro linoleic acid activation of protein kinase C
103. Arachidonic acid diacylglycerol act synergistically to activate protein kinase C in vitro and in vivo
104. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin
105. Protein-kinase C inhibitor calphostin C reduces B16 amelanotic melanoma cell adhesion to endothelium and lung colonization
106. Sangivamycin, a nucleoside analog, is a potent inhibitor of protein kinase C
107. Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine
108. 4 cell proliferation
109. Synthesis and biological activity of novel quaternary ammonium derivatives of alkylglycerols as potent inhibitors of protein kinase C
110. Synthesis and evaluation of neoplastic cell growth inhibition of 1-N-alkylamide analogues of glycero-3-phosphocholine
111. r 1700) of protein kinase C
112. A mutant protein kinase C that can transform fibroblasts
113. Phosphorylation of the multidrug resistance associated glycoprotein
114. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity
115. Alterations in protein kinase C isozymes α and β2 in activated Ha-ras containing papillomas in the absence of an increase in diacylglycerol
116. Reversal of vinblastine resistance by a new staurosporine derivative, NA-382, in P388/ADR cells
117. Identification of intracellular receptor proteins for activated protein kinase C
118. p65 Fragments, homologous to the C2 region of protein kinase C, bind to the intracellular receptors for protein kinase C
119. Inhibitory action of chlorpromazine, dibucaine and other phospholipid-interacting drugs on protein kinase C
120. Synthesis of quaternary amine ether lipids and evaluation of neoplastic cell growth inhibitory properties
121. A novel conformationally restricted protein kinase C inhibitor, Ro 31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and post-receptor stimuli
122. Modulation by palmitoylcarnitine of protein kinase C activation
123. Altered function of protein kinase C and cyclic adenosine monophosphate-dependent protein kinase in a cell line derived from a mouse lung papillary tumor
124. Phorbol diester receptor copurifies with protein kinase C
125. The role of protein kinase C in cell surface signal transduction and tumor promotion
126. Studies and perspectives of protein kinase C
127. The molecular heterogeneity of protein kinase C and its implications for cellular regulation
128. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C
129. In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells
130. Inhibition of protein kinase C by tamoxifen
131. Triphenylethylenes: a new class of protein kinase C inhibitors
132. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue
133. Transient enhancement of multidrug resistance by the bile acid deoxycholate in murine fibrosarcoma cells in vitro
134. Effect of K252a, a protein kinase inhibitor, on the proliferation of vascular smooth muscle cells
135. Reversible exposure of the pseudosubstrate domain of protein kinase C by phosphatidylserine and diacylglycerol
136. Inhibition of protein kinase C by antineoplastic agents: implications for drug resistance
137. Amino acid sequence and characterization of a protein inhibitor of protein kinase C
138. Altered growth regulation and enhanced tumorigenicity of NIH 3T3 fibroblasts transfected with protein kinase C-I cDNA
139. The bryostatins
140. Antineoplastic components of marine animals
141. Isolation and structure of bryostatin 1
142. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro
143. Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells
144. Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes and ras- and sis-transformed normal rat kidney cells
145. Stimulation of phosphatidylcholine hydrolysis, diacylglycerol release and arachadonic acid production by oncogenic ras is a consequence of protein kinase C activation
146. 2+-sensitive, phospholipid-dependent protein kinase activity in phorbol ester-treated 3T3 cells
147. Inhibition of rodent protein kinase C by the anticarcinoma agent dequalinium
148. A self-assembling protein kinase C inhibitor
149. cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway
150. Protein kinase C activity as marker for colectal cancer
151. Inhibition of protein kinase C by ether-linked lipids is not correlated with their antineoplastic activity on WEHI-3B and R6X-B15 cells
152. Identification of high-affinity phorbol ester receptor in cytosol of EL4 thymoma cells: requirement for calcium, magnesium and phospholipids
153. Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells
154. Induction of protein kinase C down-regulation by the phorbol ester TPA in a calpain/protein kinase C complex
155. Inhibition of protein kinase C by annexin V
156. Successful treatment of murine melanoma with bryostatin 1
157. Protein kinase C activity and multidrug resistance in MOLT-3 human lymphoblastic leukemia cells resistant to trimetrexate
158. Dual modulation of protein kinase C activity by sphingosine
159. Competitive inhibition by diacylglycerol of specific phorbol ester binding
160. Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells
161. Protein kinases. Regulation by autoinhibitory domains
162. A vincristine-resistant murine erythroleukemia cell line secretes a differentiation enhancing factor
163. Characterization of a membrane-associated protein kinase of multidrug-resistant HL60 cells which phosphorylates P-glycoprotein
164. Protein kinase C
165. 2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)hexanamide (NPC 15437): a novel inhibitor of protein kinase C interacting at the regulatory domain
166. UCN-01 and UCN-02, new selective inhibitors of protein kinase C
167. Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C
168. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum
169. Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glyocoprotein-mediated multi-drug resistance
170. Potent and specific inhibitors of protein kinase C of microbial origin
171. 2+ dependent protein kinase
172. Calphostin (UCN1028) and calphostin related compounds, a new class of specific and potent inhibitors of protein kinase C
173. Induction of differentiation of HL-60 cells by protein kinase C inhibitor, K252a
174. Protein kinase C inhibitor proteins: purification from sheep brain and sequence similarity to lipocortins and 14-3-3 protein
175. Multiple isoforms of a protein kinase C inhibitor (KCIP-1/14-3-3) from sheep brain
176. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
177. Activation of growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1
178. Inhibition of cell proliferation, protein kinase C and phorbol ester-induced fos expression by the dihydropridine derivative B859-35
179. Comparison of selective cytotoxicity of alkyllysophospholipids
180. Antitumor agents. 134. New shiraiachrome-A- and calphostin-C-related perylene derivatives as cytotoxic and antiviral agents and inhibitors of protein kinase C
181. Distinct patterns of phorbol ester-induced downregulation of protein kinase C activity in adriamycin-selected multidrug resistant and parental murine fibrosarcoma cells
182. Kinetic analysis of protein kinase C inhibition by staurosporine: evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates
183. Mimicry of bryostatin 1 induced phosphorylation patterns in HL-60 cells by high phorbol ester concentrations
184. Cell division arrest induced by phorbol ester in CHO cells overexpressing protein kinase C-δ subspecies
185. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation
186. Modes of inhibition by acylcarnitines, adriamycin and trifluoperazine of cardiac phospholipid-sensitive calcium-dependent protein kinase
187. The protein kinase C inhibitor staurosporine, like phorbol esters, induces the association of protein kinase C with membranes
188. Elevated levels of diacylglycerol and decreased phobol ester sensitivity in ras-transformed fibroblasts
189. Platelet activation by simultaneous actions of diacylglycerol and unsaturated fatty acids
190. Tumor-promoting activity of staurosporine, a protein kinase C inhibitor on mouse skin
191. Transfection with protein kinase Cα confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein